Sofosbuvir as backbone of interferon free treatments

Digestive and Liver Disease

Volumn 46, Issue S5, 2014, Pages S212-S220

  Bourlière, Marc ^a   Oules, Valèrie ^a   Ansaldi, Christelle ^a   Adhoute, Xavier ^a   Castellani, Paul ^a  

^a HÔPITAL SAINT JOSEPH   (France)

Author keywords

DAAs; Daclatasvir; HCV; IFN free; NS5B nucleotide inhibitors; Ribavirin; Simeprevir; Sofosbuvir

Indexed keywords

ALISPORIVIR; ANTIVIRUS AGENT; BALAPIRAVIR; BMS 986094; BOCEPREVIR; CYTOCHROME P450; DACLATASVIR; DANOPREVIR; INTERFERON; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; MERICITABINE; MICRORNA 122; NONSTRUCTURAL PROTEIN 5B; NUCLEOTIDE; PSI 938; RIBAVIRIN; RITONAVIR; SILIBININ; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VALOPICITABINE; URIDINE PHOSPHATE;

CARDIOTOXICITY; CLINICAL STUDY; DRUG EXPOSURE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHOCYTOPENIA; MIXED INFECTION; REVIEW; TREATMENT DURATION; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS; ECONOMICS; HEPACIVIRUS; HEPATITIS D, CHRONIC; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS D, CHRONIC; HUMANS; INTERFERONS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84919386783     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.09.024     Document Type: Review

References (58)

1. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. The New England Journal of Medicine 2011, 365:1014-1024.
2. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011, 364:2405-2416.
3. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. The New England Journal of Medicine 2011, 364:2417-2428.
4. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011, 364:1195-1206.
5. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011, 364:1207-1217.
6. Pawlotsky J.M. The results of phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011, 140:746-754.
7. Hezode C., Fontaine H., Dorival C., et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014, 147:132-142. e4.
8. Pawlotsky J.M. New hepatitis C therapies. Seminars in Liver Disease 2014, 34:7-8.
9. Scheel T.K., Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine 2013, 19:837-849.
10. Pawlotsky J.M. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Seminars in Liver Disease 2014, 34:22-29.
11. Aronsohn A., Jensen D. Interferon-combination strategies for the treatment of chronic hepatitis C. Seminars in Liver Disease 2014, 34:30-36.
12. Feld J.J., Kowdley K.V., Coakley E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. The New England Journal of Medicine 2014, 370:1594-1603.
13. Ferenci P., Bernstein D., Lalezari J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. The New England Journal of Medicine 2014, 370:1983-1992.
14. Zeuzem S., Jacobson I.M., Baykal T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. The New England Journal of Medicine 2014, 370:1604-1614.
15. Asselah T., Bruno S., Craxi A. HCV cirrhosis at the edge of decompensation: will ABT-450/r, ombitasvir, dasabuvir and ribavirin solve the need for treatment?. Journal of Hepatology 2014, pii:S0168-8278(14)00558-3. 10.1016/j.jhep.2014.08.018.
16. Lok A.S., Gardiner D.F., Hezode C., et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. Journal of Hepatology 2014, 60:490-499.
17. Manns M., Pol S., Jacobson I.M., et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014, pii:S0140-6736(14)61059-X. 10.1016/S0140-6736(14)61059-X.
18. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
19. Migliaccio G., Tomassini J.E., Carroll S.S., et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. Journal of Biological Chemistry 2003, 278:49164-49170.
20. Le Pogam S., Jiang W.R., Leveque V., et al. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006, 351:349-359.
21. Gane E.J., Hyland R.H., An D., et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients and genotype-1 patients with prior sofosbuvir treatment experienced. Journal of Hepatology 2014, 60(Suppl.):S3-S4. [Abstract].
22. Manns M.P., Vierling J.M., Bacon B.R., et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014, 147:366-376. e6.
23. Pawlostky J.M., Sarin S.K., Foster G., et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2or GT3 patients: SVR12 results from VITAL-1 phase 2b study. Journal of Hepatology 2012, 56:S553. [Abstract].
24. Chatterji U., Garcia-Rivera J.A., Baugh J., et al. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Antimicrobial Agents and Chemotherapy 2014, 58:3327-3334.
25. Janssen H.L., Reesink H.W., Lawitz E.J., et al. Treatment of HCV infection by targeting microRNA. The New England Journal of Medicine 2013, 368:1685-1694.
26. Esser-Nobis K., Romero-Brey I., Ganten T.M., et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 2013, 57:953-963.
27. Feld J.J. Interferon-free strategies with a nucleoside/nucleotide analogue. Seminars in Liver Disease 2014, 34:37-46.
28. Legrand-Abravanel F., Nicot F., Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opinion on Investigational Drugs 2010, 19:963-975.
29. Gane E.J., Pockros P., Zeuzem S., et al. Interferon-free treatment with a combination of mericitabine and danoprevir/R with or without ribavirin in treatment-naive HCV genotype 1 infected patients. Journal of Hepatology 2012, 56(Suppl. 2):S555. [Abstract].
30. Jensen D.M., Brunda M., Elston R., et al. Interferon-free regimen containing setrobuvir in combination with ritonavir-boosted danoprevir and ribavirin with or without mericitabine in HCV genotype 1 treatment naive patients: interim SVR4 results from the ANNAPURNA study. Hepatology 2013, 58(Suppl. 4):849A. [Abstract].
31. Papa S., Berliba A., Ghicavii N., et al. VX-135, a once daily nucleotide HCV polymerase inhibitor was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment naive patients with genotype1 HCV. Hepatology 2013, 58(Suppl. 4):852A. [Abstract].
32. Gane E., Stedman C., Garg V., et al. An interferon and ribavirin-free 12 weeks regimen of once daily VX-135 and daclatasvir in treatment naive patients with genotype1 HCV infection. Journal of Hepatology 2014, 60 Suppl.:S528-S529. [Abstract].
33. Gupta K., Seifer M., Serra I., et al. Favorable preclinical profile of IDX-21437, a novel uridine nucleotide prodrug for use in a direct-acting antiviral regimen for HCV. Journal of Hepatology 2014, 60(Suppl.):S504. [Abstract].
34. Sofia M.J., Bao D., Chang W., et al. Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. Journal of Medicinal Chemistry 2010, 53:7202-7218.
35. Marino Z., van Bommel F., Forns X., et al. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut 2014, 63:207-215.
36. Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. The New England Journal of Medicine 2013, 368:34-44.
37. Lalezari J.P., Nelson D.R., Hyland R.H., et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study. Journal of Hepatology 2013, 58(Suppl.):S346. [Abstract].
38. Osinusi A., Meissner E.G., Lee Y.J., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA: The Journal of the American Medical Association 2013, 310:804-811.
39. Sulkowski M.S., Naggie S., Lalezari J., et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA: The Journal of the American Medical Association 2014, 312:353-361.
40. Curry M.P., Forns X., Chung R.T., et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013, 58(Suppl.):314A-315A. [Abstract].
41. Samuel D., Charlton M., Gane E., et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective multicenter study. Journal of Hepatology 2014, 60(Suppl.):S499. [Abstract].
42. Lawitz E., Sulkowski M.S., Ghalib R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, pii:S0140-6736(14)61036-9. 10.1016/S0140-6736(14)61036-9.
43. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. The New England Journal of Medicine 2014, 370:211-221.
44. Lawitz E., Poordad F.F., Pang P.S., et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014, 383:515-523.
45. Afdhal N., Zeuzem S., Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. The New England Journal of Medicine 2014, 370:1889-1898.
46. Kowdley K.V., Gordon S.C., Reddy K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. The New England Journal of Medicine 2014, 370:1879-1888.
47. Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. The New England Journal of Medicine 2014, 370:1483-1493.
48. Osinusi A., Townsend K., Nelson A., et al. Use of sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV. Journal of Hepatology 2014, 60(Suppl.):S7. [Abstract].
49. Osinusi A., Marti M., Townsend K., et al. Retreatment of relapsers to sofosbuvir/ribavirin with sofosbuvir/ledipasvir: complete and rapid virologic suppression by week 4. Journal of Hepatology 2014, 60:S5-S6. [Abstract].
50. Everson G.T., Tran T.T., Towner W.J., et al. Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir+GS-5816 for 12 weeks in treatment naive patients with genotype 1-6 HCV patients. Journal of Hepatology 2014, 60(Suppl.):S46. [Abstract].
51. Gane E.J., Stedman C.A., Hyland R.H., et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin: the ELECTRON trial. Hepatology 2013, 58(Suppl.):243A. [Abstract].
52. Kohli A., Sims Z., Marti M., et al. Combination oral hepatitis C antiviral therapy for 6 or 12 weeks: results of the SYNERGY trial. Programs and abstracts of the 21st conference on retroviruses and opportunistic infections 2014, [Abstract 27 LB].
53. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. The New England Journal of Medicine 2013, 368:1878-1897.
54. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. The New England Journal of Medicine 2013, 368:1867-1877.
55. Zeuzem S., Dusheiko G.M., Salupere R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. The New England Journal of Medicine 2014, 370:1993-2001.
56. European Association for Study of Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of Hepatology 2014, 60:392-420.
57. Esteban R., Nyberg L., Lalezari J., et al. Successful retreatment with sofosbuvir-containing regimen for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy. Journal of Hepatology 2014, 60(Suppl.):S4-S5. [Abstract].
58. Ruane P.J., Ain D., Meshrekey R., et al. Sofosbuvir plus ribavirin, an interferon-free regimen in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. Journal of Hepatology 2014, 60(Suppl.):S503-S504. [Abstract].